BioCentury | Sep 9, 2020
Finance

Dozens of investors seek liquidity as Grail files for IPO ahead of commercial launches

Liquidity is looming for the long list of investors who poured $1.9 billion into Grail, now that the early cancer detection company has filed for an IPO on NASDAQ. Grail Inc. hasn’t yet set terms...
BioCentury | Aug 14, 2020
Translation in Brief

Hesperos applies organ-on-a-chip tech to ALS, Sinopharm details interim COVID-19 vaccine readout and more

...researchers have pointed to the transcription factor BRN3A...
...National Academy of Sciences article, they showed BRN3A...
...prevented the progression of renal fibrosis.TARGETSBRN3A (POU4F1) – POU class 4 homeobox 1 SMAD3...
BioCentury | Dec 7, 2018
Tools & Techniques

Germline editing gets technical

As the smoke clears from Jiankui He’s bombshell germline editing announcement, the gap between where the gene editing field is now and where it would need to be to support responsible germline editing has become...
BioCentury | Jul 12, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: June 2018

New Therapeutic Targets and Biomarkers: June 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during June 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Jul 10, 2018
Distillery Therapeutics

Cancer

INDICATION: Small cell lung cancer Patient sample and cell culture studies suggest promoting IGFBP5 expression or inhibiting POU2F3 or IGF1R could help treat POU2F3-expressing small cell lung cancer (SCLC). In tumor samples from SCLC patients,...
BioCentury | Jun 27, 2018
Preclinical News

New small cell lung cancer subtype identified

In a Genes & Development paper , scientists at Cold Spring Harbor Laboratory identified a new subtype of small cell lung cancer defined by high levels of POU class 2 homeobox 3 (POU2F3; OCT11) and suggest...
BioCentury | Jun 13, 2018
Distillery Techniques

Disease models

TECHNOLOGY: Cell models A method of directly reprogramming human adult T cells into neurons could be used to generate cell-based models of neurological diseases. The method involves transfecting primary human T cells with a combination...
BioCentury | Sep 27, 2017
Translation in Brief

Editing without translation

While last week’s Nature paper on gene editing of human embryos was a first in the U.K., it was more notable for the ground it broke than for its translational implications. Earlier studies from U.S....
BioCentury | Aug 3, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: July 2017

New Therapeutic Targets and Biomarkers: July 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2017. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Jul 25, 2017
Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies suggest nanoparticles loaded with siRNAs targeting SOX2 , OLIG2 , SALL2 , and POU3F2 could help treat the proneural subtype of glioblastoma multiforme (GBM). In two proneural GBM cell lines,...
Items per page:
1 - 10 of 36